WO2013064307A1 - Ivabradine hydrochloride form iv - Google Patents
Ivabradine hydrochloride form iv Download PDFInfo
- Publication number
- WO2013064307A1 WO2013064307A1 PCT/EP2012/068615 EP2012068615W WO2013064307A1 WO 2013064307 A1 WO2013064307 A1 WO 2013064307A1 EP 2012068615 W EP2012068615 W EP 2012068615W WO 2013064307 A1 WO2013064307 A1 WO 2013064307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ivabradine hydrochloride
- hydrochloride form
- ivabradine
- solvent system
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014010767-0A BR112014010767B1 (en) | 2011-11-04 | 2012-09-21 | ivabradine hydrochloride form iv |
US14/356,240 US9139531B2 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form IV |
LTEP12766056.1T LT2773620T (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
SI201231092T SI2773620T1 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
CA2854549A CA2854549C (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
EP12766056.1A EP2773620B1 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
RS20171010A RS56464B1 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
KR1020147015092A KR102050117B1 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
MX2014005362A MX359288B (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv. |
PL12766056T PL2773620T3 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
ES12766056.1T ES2562843T3 (en) | 2011-11-04 | 2012-09-21 | Form IV of ivabradine hydrochloride |
DK12766056.1T DK2773620T3 (en) | 2011-11-04 | 2012-09-21 | IVABRADINE HYDROCHLORIDE OF FORM IV |
AU2012331395A AU2012331395B2 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form IV |
JP2014539268A JP6359971B2 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride Form IV |
RU2014122261A RU2619121C2 (en) | 2011-11-04 | 2012-09-21 | Form iv of ivabradine hydrochloride |
ZA2014/03073A ZA201403073B (en) | 2011-11-04 | 2014-04-25 | Ivabradine hydrochloride form iv |
US14/806,224 US9309201B2 (en) | 2011-11-04 | 2015-07-22 | Process for preparating ivabradine hydrochloride form IV and methods of treatment of disease using ivabradine hydrochloride form IV |
US15/089,495 US20160289192A1 (en) | 2011-11-04 | 2016-04-02 | Ivabradine hydrochloride form iv |
HRP20171511TT HRP20171511T1 (en) | 2011-11-04 | 2017-10-09 | Ivabradine hydrochloride form iv |
CY20171101069T CY1119798T1 (en) | 2011-11-04 | 2017-10-12 | FORM IV IV Hydrochloride Ibabradine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11382339.7A EP2589594A1 (en) | 2011-11-04 | 2011-11-04 | Ivabradine hydrochloride Form IV |
EP11382339.7 | 2011-11-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/356,240 A-371-Of-International US9139531B2 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form IV |
US14/806,224 Continuation US9309201B2 (en) | 2011-11-04 | 2015-07-22 | Process for preparating ivabradine hydrochloride form IV and methods of treatment of disease using ivabradine hydrochloride form IV |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013064307A1 true WO2013064307A1 (en) | 2013-05-10 |
Family
ID=46934559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/068615 WO2013064307A1 (en) | 2011-11-04 | 2012-09-21 | Ivabradine hydrochloride form iv |
Country Status (21)
Country | Link |
---|---|
US (3) | US9139531B2 (en) |
EP (3) | EP2589594A1 (en) |
JP (3) | JP6359971B2 (en) |
KR (1) | KR102050117B1 (en) |
AU (1) | AU2012331395B2 (en) |
BR (1) | BR112014010767B1 (en) |
CA (1) | CA2854549C (en) |
CY (1) | CY1119798T1 (en) |
DK (1) | DK2773620T3 (en) |
ES (1) | ES2562843T3 (en) |
HR (1) | HRP20171511T1 (en) |
HU (1) | HUE034996T2 (en) |
LT (1) | LT2773620T (en) |
MX (1) | MX359288B (en) |
PL (1) | PL2773620T3 (en) |
PT (1) | PT2773620T (en) |
RS (1) | RS56464B1 (en) |
RU (1) | RU2619121C2 (en) |
SI (1) | SI2773620T1 (en) |
WO (1) | WO2013064307A1 (en) |
ZA (1) | ZA201403073B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102919A1 (en) | 2011-11-14 | 2013-07-11 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
EP2774606A1 (en) | 2014-02-14 | 2014-09-10 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV |
EP2781509A1 (en) | 2013-03-19 | 2014-09-24 | Chemo Research, S.L. | New polymorph of ivabradine hydrochloride and method for its preparation |
WO2015001133A1 (en) | 2013-12-12 | 2015-01-08 | Synthon B.V. | Pharmaceutical composition comprising amorphous ivabradine |
WO2015048937A1 (en) | 2013-10-02 | 2015-04-09 | Zentiva, K.S. | A solid form of ivabradine hydrochloride and (s)-mandelic acid and a pharmaceutical composition thereof |
WO2016004911A1 (en) | 2014-07-10 | 2016-01-14 | Zentiva, K.S. | A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition |
WO2016198154A1 (en) | 2015-06-11 | 2016-12-15 | Pharmathen S.A. | Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof |
EP3366282A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
EP3366281A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2589594A1 (en) * | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
ITMI20130684A1 (en) * | 2013-04-24 | 2014-10-25 | Chemo Res S L | NEW POLIMORFO OF IVABRADINA CHLORIDRATE AND METHOD FOR ITS PREPARATION |
EP3686655A4 (en) | 2017-09-19 | 2021-06-16 | Mitsui Chemicals, Inc. | Eyewear |
WO2020092288A1 (en) * | 2018-10-30 | 2020-05-07 | Amgen Inc. | Process of making ivabradine hydrochloride drug product |
IT202000025312A1 (en) | 2020-10-26 | 2022-04-26 | Cambrex Profarmaco Milano S R L | PROCESSES FOR THE PREPARATION OF IVABRADINE HCL POLYMORPHS |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534859A1 (en) | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases |
EP1589005A1 (en) | 2004-04-13 | 2005-10-26 | Les Laboratoires Servier | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts |
EP1695965A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it |
EP1695710A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form beta-d fo the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
EP1695709A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
EP1707562A1 (en) | 2005-02-28 | 2006-10-04 | Les Laboratoires Servier | Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it |
EP1775287A1 (en) | 2005-10-11 | 2007-04-18 | Les Laboratoires Servier | Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
EP1775288A1 (en) | 2005-10-11 | 2007-04-18 | Les Laboratoires Servier | Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
WO2008125006A1 (en) | 2007-04-12 | 2008-10-23 | Utopharm (Shanghai) Co., Ltd | Preparation processes for ivabradine hydrochloride and its stable crystalline form |
WO2008146308A2 (en) | 2007-05-30 | 2008-12-04 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
CN101463008A (en) | 2009-01-11 | 2009-06-24 | 山东鲁抗辰欣药业有限公司 | Ivabradine amorphous article and preparation thereof |
CN101597261A (en) | 2008-06-06 | 2009-12-09 | 北京深蓝海生物医药科技有限公司 | Amorphous ivabradine hydrochloride |
CN101768117A (en) | 2008-12-29 | 2010-07-07 | 北京德众万全药物技术开发有限公司 | New crystalline form of hydrochloric acid Ivabradine and preparation method thereof |
CN101805289A (en) | 2009-02-17 | 2010-08-18 | 成都威克药业有限责任公司 | Omega-crystal form, preparation method and medicine composite of ivabradine hydrochloride |
CN102050784A (en) | 2009-11-04 | 2011-05-11 | 扬子江药业集团北京海燕药业有限公司 | Novel method for preparing amorphous Ivabradine hydrochloride |
WO2011098582A2 (en) | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2381771T3 (en) * | 2006-11-30 | 2012-05-31 | Cadila Healthcare Limited | Procedure for the preparation of ivabradine hydrochloride |
US20100323471A1 (en) | 2008-08-21 | 2010-12-23 | Applied Materials, Inc. | Selective Etch of Laser Scribed Solar Cell Substrate |
WO2012025940A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Polymorphic form of ivabradine hydrochloride and process for preparation thereof |
EP2589594A1 (en) * | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
US9120755B2 (en) * | 2011-11-14 | 2015-09-01 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
-
2011
- 2011-11-04 EP EP11382339.7A patent/EP2589594A1/en not_active Withdrawn
-
2012
- 2012-09-21 WO PCT/EP2012/068615 patent/WO2013064307A1/en active Application Filing
- 2012-09-21 JP JP2014539268A patent/JP6359971B2/en active Active
- 2012-09-21 BR BR112014010767-0A patent/BR112014010767B1/en active IP Right Grant
- 2012-09-21 EP EP17184888.0A patent/EP3263556A1/en active Pending
- 2012-09-21 EP EP12766056.1A patent/EP2773620B1/en active Active
- 2012-09-21 DK DK12766056.1T patent/DK2773620T3/en active
- 2012-09-21 MX MX2014005362A patent/MX359288B/en active IP Right Grant
- 2012-09-21 SI SI201231092T patent/SI2773620T1/en unknown
- 2012-09-21 AU AU2012331395A patent/AU2012331395B2/en active Active
- 2012-09-21 PL PL12766056T patent/PL2773620T3/en unknown
- 2012-09-21 RS RS20171010A patent/RS56464B1/en unknown
- 2012-09-21 CA CA2854549A patent/CA2854549C/en active Active
- 2012-09-21 HU HUE12766056A patent/HUE034996T2/en unknown
- 2012-09-21 PT PT127660561T patent/PT2773620T/en unknown
- 2012-09-21 KR KR1020147015092A patent/KR102050117B1/en active IP Right Grant
- 2012-09-21 ES ES12766056.1T patent/ES2562843T3/en active Active
- 2012-09-21 US US14/356,240 patent/US9139531B2/en active Active
- 2012-09-21 LT LTEP12766056.1T patent/LT2773620T/en unknown
- 2012-09-21 RU RU2014122261A patent/RU2619121C2/en active
-
2014
- 2014-04-25 ZA ZA2014/03073A patent/ZA201403073B/en unknown
-
2015
- 2015-07-22 US US14/806,224 patent/US9309201B2/en active Active
-
2016
- 2016-04-02 US US15/089,495 patent/US20160289192A1/en not_active Abandoned
-
2017
- 2017-05-30 JP JP2017106708A patent/JP2017178965A/en not_active Withdrawn
- 2017-10-09 HR HRP20171511TT patent/HRP20171511T1/en unknown
- 2017-10-12 CY CY20171101069T patent/CY1119798T1/en unknown
-
2018
- 2018-04-09 JP JP2018074972A patent/JP2018123154A/en active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534859A1 (en) | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases |
EP1589005A1 (en) | 2004-04-13 | 2005-10-26 | Les Laboratoires Servier | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts |
EP1695965A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it |
EP1695710A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form beta-d fo the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
EP1695709A1 (en) | 2005-02-28 | 2006-08-30 | Les Laboratoires Servier | Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
EP1707562A1 (en) | 2005-02-28 | 2006-10-04 | Les Laboratoires Servier | Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it |
EP1956005A1 (en) | 2005-10-11 | 2008-08-13 | Les Laboratoires Servier | Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
EP1775288A1 (en) | 2005-10-11 | 2007-04-18 | Les Laboratoires Servier | Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
EP1775287A1 (en) | 2005-10-11 | 2007-04-18 | Les Laboratoires Servier | Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
WO2008125006A1 (en) | 2007-04-12 | 2008-10-23 | Utopharm (Shanghai) Co., Ltd | Preparation processes for ivabradine hydrochloride and its stable crystalline form |
WO2008146308A2 (en) | 2007-05-30 | 2008-12-04 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
CN101597261A (en) | 2008-06-06 | 2009-12-09 | 北京深蓝海生物医药科技有限公司 | Amorphous ivabradine hydrochloride |
CN101768117A (en) | 2008-12-29 | 2010-07-07 | 北京德众万全药物技术开发有限公司 | New crystalline form of hydrochloric acid Ivabradine and preparation method thereof |
CN101463008A (en) | 2009-01-11 | 2009-06-24 | 山东鲁抗辰欣药业有限公司 | Ivabradine amorphous article and preparation thereof |
CN101805289A (en) | 2009-02-17 | 2010-08-18 | 成都威克药业有限责任公司 | Omega-crystal form, preparation method and medicine composite of ivabradine hydrochloride |
CN102050784A (en) | 2009-11-04 | 2011-05-11 | 扬子江药业集团北京海燕药业有限公司 | Novel method for preparing amorphous Ivabradine hydrochloride |
WO2011098582A2 (en) | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
Non-Patent Citations (2)
Title |
---|
BRITAIN ET AL: "Polymorphism in Pharmaceutical Solids passage", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, XX, XX, 1 January 1999 (1999-01-01), pages 235 - 238, XP002278123 * |
BRITTAIN: "X-RAY DIFFRACTION III: PHARMACEUTICAL APPLICATIONS", SPECTROSCOPY, ELSEVIER, AMSTERDAM, NL, vol. 16, 1 January 2001 (2001-01-01), pages 142 - 150, XP009082169, ISSN: 0712-4813 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102919A1 (en) | 2011-11-14 | 2013-07-11 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
EP3156399A1 (en) * | 2011-11-14 | 2017-04-19 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
EP2781509B1 (en) | 2013-03-19 | 2019-11-27 | Chemo Research, S.L. | New polymorph of ivabradine hydrochloride and method for its preparation |
EP2781509A1 (en) | 2013-03-19 | 2014-09-24 | Chemo Research, S.L. | New polymorph of ivabradine hydrochloride and method for its preparation |
WO2015048937A1 (en) | 2013-10-02 | 2015-04-09 | Zentiva, K.S. | A solid form of ivabradine hydrochloride and (s)-mandelic acid and a pharmaceutical composition thereof |
WO2015001133A1 (en) | 2013-12-12 | 2015-01-08 | Synthon B.V. | Pharmaceutical composition comprising amorphous ivabradine |
US20170014422A1 (en) * | 2014-02-14 | 2017-01-19 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph iv |
WO2015120920A1 (en) * | 2014-02-14 | 2015-08-20 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph iv |
EP2774606B1 (en) | 2014-02-14 | 2019-01-30 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV |
EP2774606A1 (en) | 2014-02-14 | 2014-09-10 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV |
WO2016004911A1 (en) | 2014-07-10 | 2016-01-14 | Zentiva, K.S. | A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition |
WO2016198154A1 (en) | 2015-06-11 | 2016-12-15 | Pharmathen S.A. | Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof |
EP3366282A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
EP3366281A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
WO2018158214A1 (en) | 2017-02-28 | 2018-09-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
WO2018158304A1 (en) | 2017-02-28 | 2018-09-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012331395B2 (en) | Ivabradine hydrochloride form IV | |
US20230322680A1 (en) | Crystalline forms of pitavastatin calcium | |
JP4614870B2 (en) | Aripiprazole anhydrous crystals, methods for their production and formulations containing them | |
TW200927732A (en) | Crystalline forms of erlotinib HCl and formulations thereof | |
KR20170057441A (en) | Crystal Form of Bisulfate of JAK Inhibitor and Preparation Method Therefor | |
US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof | |
WO2019086509A1 (en) | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor | |
MC MK et al. | 08184 Palau-solità i Plegamans Barcelona (ES) | |
WO2007084761A1 (en) | Maleate salt of tegaserod and crystalline forms thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12766056 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012766056 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012766056 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014539268 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/005362 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2854549 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14356240 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2012331395 Country of ref document: AU Date of ref document: 20120921 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147015092 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014122261 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014010767 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014010767 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140505 |
|
ENP | Entry into the national phase |
Ref document number: 112014010767 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140505 |